Consort has completed its acquisition of Aesica Holdco. The acquisition is directly in line with Consort's articulated strategy of diversifying into adjacent markets and technologies to capture additional value in the drug/device supply chain.

Aesica is a European pharmaceutical contract development and manufacturing organization (CDMO), providing contract development and manufacturing services for finished dose and active pharmaceutical ingredients to the global pharmaceutical industry. Consort Medical is a global, single source drug and delivery device CDMO.

Jon Glenn, Consort's CEO, said, "We are excited by the acquisition of Aesica, which represents a very strong fit with our existing strategy of diversifying into adjacent markets and technologies to capture additional value in the drug/device supply chain.”

Dr. Robert Hardy, chief executive, Aesica, said, “Our position as a pharmaceutical CDMO is now further strengthened in the global market place through the alignment Aesica has with Bespak, as part of the enlarged Consort Medical group. With our collective strengths, we will continue to provide high quality pharmaceutical contract development and manufacturing services internationally."

Financial details have not been released.